

## **Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors**

**Oxford, UK, 21<sup>st</sup> November 2007.** Oxford Genome Sciences (UK) Ltd “OGeS” announces today that Christopher Hibberd, currently CEO at Astute Medical, Inc. and formerly Senior Vice President Corporate Development at Biosite Incorporated, has joined its Board of Directors.

Christopher Hibberd brings over 15 years of experience in business strategy and corporate development to OGeS. Hibberd is currently working as CEO of Astute Medical, Inc. and prior to that worked for 10 years at Biosite, as SVP Corporate Development, where he was responsible for the identification and pursuit of strategic business opportunities including mergers, acquisitions, partnerships and alliances as well as for developing long-range strategic plans. Prior to joining Biosite, Hibberd was manager at the Boston Consulting Group and was responsible for leading international consultants and client case teams in developing and implementing value-creating strategies for businesses in a variety of industry sectors. Prior to that he held consulting positions at various companies and also was a development engineer for Albright & Wilson Americas from 1987 to 1990.

Hibberd received a chemical engineering degree from the University of Toronto, Canada and earned a master’s degree in business administration from the University of Western Ontario, Canada.

“I am very pleased to welcome Christopher to OGeS’ Board of Directors. I am confident that his broad expertise will be valuable to support OGeS’ corporate development at a time when we are transitioning from target discovery to building our own product pipeline of therapeutic antibodies”, commented Dr Christian Rohlf, CEO of OGeS.

“Today’s announcement also highlights the excellent working relationship that we developed with Christopher when he was at Biosite, our partner for the development of diagnostics for cancer based on our unique OGAP<sup>®</sup> protein database,” he added.

Christopher Hibberd, commenting on today’s announcement said, “I am happy to be joining the Board of OGeS at such an exciting time for the company and I look forward to working with them as they develop an industry leading portfolio of antibody products for the diagnosis and treatment of cancer.”

- Ends-

### **About Oxford Genome Sciences**

Oxford Genome Sciences (OGeS) is focused on the development of targeted medicines for oncology. The company uses OGAP<sup>®</sup>, which it has developed into the world’s largest cancer protein database, to discover novel clinically relevant drug targets and diagnostics.

OGeS’ strategy is to use its unique and integrated OGAP<sup>®</sup> discovery platform in alliances with the world’s leading antibody companies to develop OGeS targets into new antibody therapeutics and diagnostics that will deliver innovative and cost-effective medicines to fulfil unmet patient needs in the field of cancer. The company has signed a number of collaborations in the area of cancer, which are together designed to achieve OGeS’ objective of developing novel personalised solutions to the management of cancer. Specifically in 2006, OGeS entered into partnerships with Medarex to discover, develop and commercialise new human antibody therapeutics for the treatment of cancers and with Biosite to develop a new diagnostic protein panel for relapsing colorectal cancer. In parallel, OGeS provides biomarker discovery and screening services to pharmaceutical and biotechnology companies.

OGeS, a privately held company, was formed in 2004 and is based near Oxford, UK.

**About OGAP®**

Oxford Genome Anatomy Project (OGAP) holds the world's largest proprietary collection of proteins represented by the database, which contains over one million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over eight million SNPs and haplotypes. The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities.

OGAP® is a registered trade mark of Oxford Genome Sciences (UK) Ltd.

For further information, please see [www.oxfordgenomesciences.com](http://www.oxfordgenomesciences.com)

**For further information, please contact:**

**Oxford Genome Sciences**

Dr Christian Rohlf, Chief Executive Officer  
Tel: +44 (0)1235 861770  
[christian.rohlf@oxfordgenomesciences.com](mailto:christian.rohlf@oxfordgenomesciences.com)

**Citigate Dewe Rogerson**

David Dible, Valerie Auffray  
Tel: +44 (0)207 638 9571  
[valerie.auffray@citigatedr.co.uk](mailto:valerie.auffray@citigatedr.co.uk)